CD4 and neoplasm: PDAC inherently have an immunosuppressive tumor immune microenvironment (TIME).[5] The TIME of PDAC is infiltrated with T‐regulatory cells (Tregs), M2 polarized tumor‐associated macrophages (TAMs), and myeloid‐derived suppressive cells, which block anti‐tumor activities of effector CD4+ and CD8+ T cells.[6] Immunotherapy, inclusive of immune checkpoint inhibitors (ICIs) and agonist monoclonal antibodies (mAb), is a promising treatment avenue, as it harnesses the host immune system to target the TIME.